
4DMEDICAL LIMITED ACN 161 684 831

ADDENDUM TO 2026 NOTICE OF ANNUAL GENERAL MEETING

4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) hereby gives notice to shareholders of the Company that, in relation to the Company’s Notice of Annual General Meeting dated 24 September 2026 (**Notice of Meeting**) in respect of an Annual General Meeting of Shareholders to be held 10:00am (AEDT), Wednesday, 28 October 2026 at Forum Rooms 2+3, Melbourne Connect, Mezzanine Floor, 700 Swanston Street, Carlton VIC 3053 and online via the online platform at: <https://meetings.openbriefing.com/4DX26> (**Meeting**), the Directors have determined to issue this addendum (**Addendum**) for the purposes set out below.

Defined terms in the Notice of Meeting have the same meaning in this Addendum unless otherwise stated.

NEW RESOLUTION

The Notice of Meeting is amended to include an additional resolution (Item 12) as set out in this Addendum in the business to be considered at the Meeting. The additional resolution is proposed to ratify the appointment of Prof Christine Jenkins as a Director, since Prof Jenkins must not hold office (without re-election) past the Meeting in accordance with the requirements of ASX Listing Rule 14.4. The below resolution is added to the Agenda in the Notice after Item 11.

REPLACEMENT PROXY FORM

Annexed to this Addendum is a replacement Proxy Form (**Replacement Proxy Form**). To ensure clarity of voting instructions by Shareholders on the Resolutions to be considered at the Meeting, Shareholders are advised that:

- (a) If you have already completed and returned the Proxy Form annexed with the Notice of Meeting (**Original Proxy Form**) and you wish to change your original vote for Items 1 to 11 or cast votes for the additional Item 12 Resolution, **you must complete and return the Replacement Proxy Form**.
- (b) If you have already completed and returned the Original Proxy Form and **you do not wish to change your original vote for Resolutions 1 to 11 or vote on the additional Item 12 Resolution, you do not need to take any action** as the earlier submitted Original Proxy Form will be accepted by the Company for Resolutions 1 to 11 unless you submit a Replacement Proxy Form. For the sake of clarity, the Company notes that if you do not lodge a Replacement Proxy Form, you will not have cast a vote on the additional Item 12 Resolution.
- (c) If you have not yet completed and returned a Proxy Form and you wish to vote on the Resolutions in the Notice as supplemented by this Addendum, please complete and return the Replacement Proxy Form.

ENQUIRIES

Shareholders are invited to contact the Company Secretary, Hamish George at companysecretary@4dmedical.com if they have any queries in respect of the matters set out in this Addendum.

By order of the Board

Hamish George, Company Secretary

16 October 2026

SUPPLEMENTARY BUSINESS OF THE MEETING

The following additional Resolution is inserted in the Notice of Meeting as follows:

Item 12. Election of Director, Prof Christine Jenkins

To consider, and if thought fit, to pass, with or without amendment, the following resolution as an ordinary resolution:

“That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.4, and for all other purposes, Prof Christine Jenkins, a non-executive director appointed on 23 September 2026, and being eligible, is re-elected as a director.”

SUPPLEMENTARY EXPLANATORY STATEMENT

Item 12. Election of Director, Prof Christine Jenkins

Background

The Constitution allows the Directors to appoint at any time a person to be a Director either to fill a casual vacancy or as an addition to the existing Directors, but only where the total number of Directors does not at any time exceed the maximum number specified by the Constitution.

Pursuant to the Constitution and Listing Rule 14.4, any Director so appointed holds office only until the next annual general meeting and is then eligible for election by Shareholders.

Prof Christine Jenkins, having been appointed by other Directors on 23 September 2026 in accordance with the Constitution, will retire in accordance with the Constitution and Listing Rule 14.4 and being eligible, seeks election from Shareholders pursuant to this Item 12.

If Item 12 is passed, Prof Christine Jenkins will be re-elected as a Director of the Company.

If Item 12 is not passed, Prof Christine Jenkins will not be re-elected and she will retire as a Director. The Board may consider an appointment to fill a casual vacancy pursuant to the Constitution, with ratification at the Company's next AGM.

Biography

Professor Jenkins is one of Australia's most influential figures in respiratory medicine. Over a distinguished career spanning four decades, she has combined clinical practice, research, education and policy leadership at the highest levels of the profession. She served as a senior staff specialist in respiratory medicine at Concord Hospital for 40 years, has led more than 34 clinical trials as principal investigator and authored more than 320 publications.

Her work has focused on improving diagnostic pathways and outcomes for patients with respiratory disease, particularly those presenting with breathlessness, COPD and asthma. She currently leads a Medical Research Future Fund trial developing a digital tool to assist general practitioners in assessing and managing patients with breathlessness.

Professor Jenkins has held many of the most senior leadership positions in Australian respiratory medicine, including Chair of Lung Foundation Australia, the Thoracic Society of Australia and New Zealand and the National Asthma Council. She has also played a central

role in shaping national respiratory health policy, clinical standards and patient advocacy initiatives.

She was appointed a Member of the Order of Australia for services to respiratory medicine as a clinician, administrator and educator. She is a Fellow of both the Thoracic Society of Australia and New Zealand and the Australian Academy of Health and Medical Sciences.

Directors' recommendation

Prof Christine Jenkins has a material personal interest in the outcome of Item 12 and accordingly declines to make a recommendation in respect of this Resolution.

The Board (other than Prof Christine Jenkins) considers Prof Christine Jenkins' skills and experience will continue to enhance the Board's ability to perform its role. Accordingly, the Board (with Prof Christine Jenkins abstaining) supports the election of Prof Christine Jenkins and recommends that Shareholders vote in favour of Item 12.